These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1148 related articles for article (PubMed ID: 17519148)
1. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148 [TBL] [Abstract][Full Text] [Related]
2. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
3. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560 [TBL] [Abstract][Full Text] [Related]
4. Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE. Rad M; Burggraaf J; de Kam ML; Cohen AF; Kluft C Contraception; 2012 Sep; 86(3):231-7. PubMed ID: 22445437 [TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Teichmann A Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257 [TBL] [Abstract][Full Text] [Related]
6. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. White T; Ozel B; Jain JK; Stanczyk FZ Contraception; 2006 Oct; 74(4):293-6. PubMed ID: 16982228 [TBL] [Abstract][Full Text] [Related]
7. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Rad M; Kluft C; Ménard J; Burggraaf J; de Kam ML; Meijer P; Sivin I; Sitruk-Ware RL Am J Obstet Gynecol; 2006 Jul; 195(1):72-7. PubMed ID: 16545330 [TBL] [Abstract][Full Text] [Related]
8. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400 [TBL] [Abstract][Full Text] [Related]
9. Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol. Archer DF; Thomas MA; Conard J; Merkatz RB; Creasy GW; Roberts K; Plagianos M; Blithe D; Sitruk-Ware R Contraception; 2016 Jan; 93(1):58-64. PubMed ID: 26408374 [TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene. Lepot MR; Gaspard UJ Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343 [TBL] [Abstract][Full Text] [Related]
11. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study. Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061 [TBL] [Abstract][Full Text] [Related]
12. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel]. Elkik F; Basdevant A; Corvol P Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250 [TBL] [Abstract][Full Text] [Related]
13. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. Creasy GW; Fisher AC; Hall N; Shangold GA J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776 [TBL] [Abstract][Full Text] [Related]
14. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
15. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264 [TBL] [Abstract][Full Text] [Related]
16. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499 [TBL] [Abstract][Full Text] [Related]
17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
18. Long-term profile of a new progestin. Lippman J Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189 [TBL] [Abstract][Full Text] [Related]
19. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. Larsson-Cohn U; Wallentin L; Zador G Horm Metab Res; 1979 Jul; 11(7):437-40. PubMed ID: 225252 [TBL] [Abstract][Full Text] [Related]
20. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Winkler UH; Sudik R Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]